Thalidomide treatment of resistant or relapsed multiple myeloma patients.

@article{Hus2001ThalidomideTO,
  title={Thalidomide treatment of resistant or relapsed multiple myeloma patients.},
  author={Marek Hus and Anna Dmoszyńska and Maria Soroka-Wojtaszko and Dariusz Jawniak and Wojciech Legie{\'c} and H Ciepnuch and A. Hellmann and Teresa Wolska-Smoleń and Aleksander Bartłomiej Skotnicki and Joanna Ma{\~n}ko},
  journal={Haematologica},
  year={2001},
  volume={86 4},
  pages={404-8}
}
BACKGROUND AND OBJECTIVES Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy. Literature data show prolonged survival in patients with advanced multiple myeloma treated with thalidomide but the optimal time and dose of thalidomide treatment remain to be established. DESIGN AND METHODS We have treated 53 refractory or relapsed myeloma patients with thalidomide (Grunenthal, Aachen). The patients received… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Antineoplastic drug-induced bradyarrhythmias.

Expert opinion on drug safety • 2012
View 2 Excerpts

Advances in oral therapy in the treatment of multiple myeloma.

Clinical journal of oncology nursing • 2006
View 2 Excerpts

Similar Papers

Loading similar papers…